EA008465B1 - γ-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT - Google Patents
γ-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT Download PDFInfo
- Publication number
- EA008465B1 EA008465B1 EA200600320A EA200600320A EA008465B1 EA 008465 B1 EA008465 B1 EA 008465B1 EA 200600320 A EA200600320 A EA 200600320A EA 200600320 A EA200600320 A EA 200600320A EA 008465 B1 EA008465 B1 EA 008465B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- ivabradine hydrochloride
- crystalline form
- accordance
- ivabradine
- degrees
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
- C07D223/14—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D223/16—Benzazepines; Hydrogenated benzazepines
-
- G—PHYSICS
- G04—HOROLOGY
- G04F—TIME-INTERVAL MEASURING
- G04F1/00—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers
- G04F1/04—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity
- G04F1/06—Apparatus which can be set and started to measure-off predetermined or adjustably-fixed time intervals without driving mechanisms, e.g. egg timers by movement or acceleration due to gravity by flowing-away of a prefixed quantity of fine-granular or liquid materials, e.g. sand-glass, water-clock
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
- H04L51/21—Monitoring or handling of messages
- H04L51/214—Monitoring or handling of messages using selective forwarding
-
- H—ELECTRICITY
- H04—ELECTRIC COMMUNICATION TECHNIQUE
- H04L—TRANSMISSION OF DIGITAL INFORMATION, e.g. TELEGRAPHIC COMMUNICATION
- H04L51/00—User-to-user messaging in packet-switching networks, transmitted according to store-and-forward or real-time protocols, e.g. e-mail
- H04L51/21—Monitoring or handling of messages
- H04L51/212—Monitoring or handling of messages using filtering or selective blocking
Abstract
Description
Настоящее изобретение относится к новой γ-кристаллической форме гидрохлорида ивабрадина формулы (I), к способу ее получения и к фармацевтическим композициям, которые ее содержат.The present invention relates to a new γ-crystalline form of ivabradine hydrochloride of formula (I), to a method for its preparation and to pharmaceutical compositions that contain it.
Ивабрадин и его соли присоединения с фармацевтически приемлемой кислотой, и более предпочтительно его гидрохлорид, обладают ценными фармакологическими и терапевтическими свойствами, в особенности брадикардическими свойствами, что делает эти соединения пригодными для лечения или профилактики различных клинических состояний ишемии миокарда, таких как стенокардия, инфаркт миокарда и ассоциированные нарушения ритма, а также различных патологий, связанных с нарушениями ритма, в особенности суправентирулярных нарушений ритма, и при сердечной недостаточности.Ivabradine and its addition salts with a pharmaceutically acceptable acid, and more preferably its hydrochloride, possess valuable pharmacological and therapeutic properties, especially bradycardic properties, which makes these compounds suitable for the treatment or prevention of various clinical conditions of myocardial ischemia, such as angina pectoris, myocardial infarction and associated rhythm disturbances, as well as various pathologies associated with rhythm disturbances, especially supraventular rhythm disturbances, and in cardiac liver failure.
Получение и терапевтическое применение ивабрадина и его солей присоединения с фармацевтически приемлемой кислотой, и более предпочтительно его гидрохлорида, описано в заявке на европейский патент ЕР 0534859.The preparation and therapeutic use of ivabradine and its addition salts with a pharmaceutically acceptable acid, and more preferably its hydrochloride, is described in European patent application EP 0534859.
Учитывая фармацевтическую ценность этого соединения, чрезвычайно важным является его получение с очень хорошей чистотой. Также является важной возможность его синтеза с помощью способа, который легко можно осуществить в промышленном масштабе, в особенности в форме, которая позволяет осуществлять быструю фильтрацию и сушку. Кроме того, эта форма должна быть в полной мере воспроизводима, легко подвергаться превращению в лекарственные формы и являться достаточно стабильной, что позволяет ее хранить в течение длительного времени без особых требований к температуре хранения, освещенности или уровню кислорода.Given the pharmaceutical value of this compound, it is extremely important to obtain it with very good purity. It is also important that it can be synthesized using a method that can be easily carried out on an industrial scale, especially in a form that allows fast filtration and drying. In addition, this form must be fully reproducible, easily converted to dosage forms, and be stable enough that it can be stored for a long time without any special requirements for storage temperature, illumination, or oxygen level.
В заявке на европейский патент ЕР 0534859 описан способ синтеза ивабрадина и его гидрохлорида. Однако в этом документе не описаны условия получения ивабрадина в форме, которая обладает этими свойствами, которые могут быть воспроизведены.European patent application EP 0534859 describes a method for the synthesis of ivabradine and its hydrochloride. However, this document does not describe the conditions for the production of ivabradine in a form that has these properties that can be reproduced.
Сейчас заявителем было обнаружено, что определенная соль ивабрадина, а именно гидрохлорид, может быть получена в кристаллической форме, которая точно определена и обладает ценными характеристиками стабильности и способностями к переработке.It has now been discovered by the applicant that a specific salt of ivabradine, namely the hydrochloride salt, can be obtained in crystalline form, which is precisely defined and has valuable stability characteristics and processability.
В частности, настоящее изобретение относится к γ-кристаллической форме гидрохлорида ивабрадина, которая характеризуется следующей рентгеновской порошковой дифрактограммой, измеренной при помощи дифрактометра РАХа1уйса1 Х'Рег! Рго совместно с детектором Х'Се1ега1ог и выраженной на основе положения луча (брэгговский угол 2Θ, выраженный в градусах), высоты луча (выраженной в импульсах), площади луча (выраженной в импульсаххградусы), ширины луча при половине высоты (РАУНМ, выраженной в градусах) и межплоскостного расстояния ά (выраженного в А).In particular, the present invention relates to a γ-crystalline form of ivabradine hydrochloride, which is characterized by the following X-ray powder diffraction pattern, measured using a PAX-1UIS1 X'Reg diffractometer! Rgo together with the X'Se1eg1og detector and expressed on the basis of the beam position (Bragg angle 2 угол, expressed in degrees), beam height (expressed in pulses), beam area (expressed in pulses of degree), beam width at half height (RAUNM, expressed in degrees ) and interplanar distance ά (expressed in A).
- 1 008465- 1 008465
Изобретение также относится к способу получения γ-кристаллической формы гидрохлорида ивабрадина, который характеризуется тем, что смесь гидрохлорида ивабрадина и 2-этоксиэтанола, смесь гидрохлорида ивабрадина, 2-этоксиэтанола и воды или смесь гидрохлорида ивабрадина, этанола и воды нагревают до полного растворения, затем охлаждают до завершения кристаллизации и продукт собирают путем фильтрации.The invention also relates to a method for producing a γ-crystalline form of ivabradine hydrochloride, which is characterized in that a mixture of ivabradine hydrochloride and 2-ethoxyethanol, a mixture of ivabradine hydrochloride, 2-ethoxyethanol and water, or a mixture of ivabradine hydrochloride, ethanol and water are heated to complete dissolution, then cooled until crystallization is complete and the product is collected by filtration.
В способе кристаллизации в соответствии с изобретением можно применять гидрохлорид ивабрадина, полученный при помощи любого способа, например гидрохлорид ивабрадина, полученный способом, описанным в заявке на европейский патент ЕР 0534859.In the crystallization method in accordance with the invention, ivabradine hydrochloride obtained by any method, for example ivabradine hydrochloride obtained by the method described in European patent application EP 0534859, can be used.
Раствор предпочтительно можно затравливать при осуществлении стадии охлаждения.The solution can preferably be seeded during the cooling step.
Изобретение также относится к фармацевтическим композициям, которые содержат в качестве активного компонента γ-кристаллическую форму гидрохлорида ивабрадина совместно с одним или более подходящими инертными нетоксичными наполнителями. Среди фармацевтических композиций согласно изобретению особенно можно отметить те, которые являются пригодными для перорального, парентерального (внутривенного или подкожного) или назального введения, таблетки или драже, подъязычные таблетки, желатиновые капсулы, лепешки, суппозитории, кремы, мази, кожные гели, составы для инъекций, суспензии для питья.The invention also relates to pharmaceutical compositions which contain, as an active component, a γ-crystalline form of ivabradine hydrochloride together with one or more suitable inert non-toxic excipients. Among the pharmaceutical compositions according to the invention, those which are suitable for oral, parenteral (intravenous or subcutaneous) or nasal administration, tablets or dragees, sublingual tablets, gelatin capsules, lozenges, suppositories, creams, ointments, skin gels, injectable compositions can be especially noted. suspensions for drinking.
Полезная дозировка может изменяться в зависимости от природы и тяжести расстройства, пути введения, а также от возраста и веса пациента. Дозировка изменяется от 1 до 500 мг в сутки на одно или больше введений.The useful dosage may vary depending on the nature and severity of the disorder, the route of administration, as well as the age and weight of the patient. The dosage varies from 1 to 500 mg per day for one or more administrations.
Последующие примеры иллюстрируют изобретение.The following examples illustrate the invention.
Спектр порошковой дифракции рентгеновских лучей измеряли в следующих экспериментальных условиях:The powder X-ray diffraction spectrum was measured under the following experimental conditions:
ΡΑΝηΙνОса! Х'РеП Рго дифрактометр, Х'Сс1сгаЮг детектор, камера для регулирования температуры; напряжение: 45 кВ;ΡΑΝηΙνHasp! X'ReP Rgo diffractometer, X'Cs1sgaYug detector, camera for temperature control; voltage: 45 kV;
сила тока: 40 мА;current strength: 40 mA;
установка: Θ-Θ;setting: Θ-Θ;
никелевый фильтр: (Κβ);nickel filter: (Κβ);
щель Соллера между падающим лучом и отраженным лучом: 0,04 рад;Soller gap between the incident beam and the reflected beam: 0.04 rad;
постоянный угол отклонения щелей: 1/8°;constant angle of deviation of cracks: 1/8 °;
ширма: 10 мм;screen: 10 mm;
антирассеивающая щель: 1/4°;anti-scattering gap: 1/4 °;
метод измерения: непрерывный от 3 до 30°, с возрастанием на 0,017°;measurement method: continuous from 3 to 30 °, with an increase of 0.017 °;
время измерения на шаг: 19,7 с;measurement time per step: 19.7 s;
общее время: 4 мин 32 с;total time: 4 min 32 s;
скорость измерения: 0,108 °/с;measurement speed: 0.108 ° / s;
температура измерения: температура окружающей среды.measurement temperature: ambient temperature.
Пример 1. γ-Кристаллическая форма гидрохлорида ивабрадина.Example 1. The γ-crystalline form of ivabradine hydrochloride.
мл 2-этоксиэтанола предварительно нагревали до 80°С и затем порциями, при перемешивании, добавляли 8,4 г гидрохлорида ивабрадина, полученного согласно способу, описанному в заявке на европейский патент ЕР 0534859, и смесь нагревали при 80°С до завершения растворения. После возвращения температуры до температуры окружающей среды раствор выдерживали в течение 8 дней, а затем образованные кристаллы собирали путем фильтрации и промывали циклогексаном.ml of 2-ethoxyethanol was preheated to 80 ° C and then, portionwise, with stirring, 8.4 g of ivabradine hydrochloride prepared according to the method described in European patent application EP 0534859 were added, and the mixture was heated at 80 ° C until complete dissolution. After returning the temperature to ambient temperature, the solution was kept for 8 days, and then the formed crystals were collected by filtration and washed with cyclohexane.
Содержание воды в полученных кристаллах, определенное с помощью кулонометрии, составляло 3,5%, что соответствует моногидрату.The water content in the obtained crystals, determined by coulometry, was 3.5%, which corresponds to monohydrate.
Рентгеновская порошковая дифрактограмма.X-ray powder diffractogram.
Профиль рентгеновской порошковой дифракции (углы дифракции) γ-формы гидрохлорида ивабрадина установлен для значимых лучей, объединенных в следующей таблице.The X-ray powder diffraction profile (diffraction angles) of the γ-form of ivabradine hydrochloride is set for the significant rays combined in the following table.
Claims (6)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0501989A FR2882555B1 (en) | 2005-02-28 | 2005-02-28 | CRYSTALLINE GAMMA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
Publications (2)
Publication Number | Publication Date |
---|---|
EA200600320A1 EA200600320A1 (en) | 2006-08-25 |
EA008465B1 true EA008465B1 (en) | 2007-06-29 |
Family
ID=34954955
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200600320A EA008465B1 (en) | 2005-02-28 | 2006-02-27 | γ-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT |
Country Status (42)
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2619121C2 (en) * | 2011-11-04 | 2017-05-12 | Уркуима, С.А. | Form iv of ivabradine hydrochloride |
Families Citing this family (35)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2868777B1 (en) * | 2004-04-13 | 2006-05-26 | Servier Lab | NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID |
FR2882554B1 (en) * | 2005-02-28 | 2007-05-04 | Servier Lab | IVABRADINE HYDROCHLORIDE BETA D-CRYSTALLINE FORM, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2882555B1 (en) * | 2005-02-28 | 2007-05-04 | Servier Lab | CRYSTALLINE GAMMA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2882556B1 (en) * | 2005-02-28 | 2007-05-04 | Servier Lab | CRYSTALLINE GAMMA D FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2882553B1 (en) * | 2005-02-28 | 2007-05-04 | Servier Lab | CRYSTALLINE BETA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2891827B1 (en) * | 2005-10-11 | 2007-12-28 | Servier Lab | CRYSTALLINE DELTAD FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2891826B1 (en) * | 2005-10-11 | 2007-12-28 | Servier Lab | CRYSTALLINE FORM 6 OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2894825B1 (en) * | 2005-12-21 | 2010-12-03 | Servier Lab | NOVEL ASSOCIATION OF SINUSAL IF CURRENT INHIBITOR AND CONVERSION ENZYME INHIBITOR AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
ES2381771T3 (en) | 2006-11-30 | 2012-05-31 | Cadila Healthcare Limited | Procedure for the preparation of ivabradine hydrochloride |
CN101353325B (en) * | 2007-07-27 | 2011-11-09 | 上海优拓医药科技有限公司 | Stable Ivabradine crystal and preparation thereof |
EP2471780B1 (en) | 2007-05-30 | 2014-11-26 | Ind-Swift Laboratories Limited | Crystalline Ivabradine Oxalate Salts and Polymorphs Thereof |
ES2402765T3 (en) | 2008-12-22 | 2013-05-08 | Krka, D.D., Novo Mesto | Ivabradine preparation procedure |
CN101774969B (en) | 2009-01-13 | 2012-07-04 | 江苏恒瑞医药股份有限公司 | Ivabradine sulfate and method for preparing type I crystal thereof |
WO2010128525A2 (en) | 2009-05-04 | 2010-11-11 | Dinesh Shantilal Patel | A formulation of ivabradine for treating the cardiovascular disease |
SI2902384T1 (en) | 2010-02-12 | 2018-03-30 | Krka, D.D., Novo Mesto | Form of ivabradine hydrochloride |
HUP1000245A2 (en) | 2010-05-07 | 2011-11-28 | Richter Gedeon Nyrt | Industrial process for the production ivabradin salts |
TWI499587B (en) * | 2010-06-03 | 2015-09-11 | Jiangsu Hengrui Medicine Co | Method for the preparation of ivabradine sulfate and form i thereof |
WO2012025940A1 (en) | 2010-08-25 | 2012-03-01 | Cadila Healthcare Limited | Polymorphic form of ivabradine hydrochloride and process for preparation thereof |
EP2726462B1 (en) | 2011-08-02 | 2017-03-22 | Sandoz AG | Acetone solvate of ivabradine hydrochloride |
EP2773621B1 (en) | 2011-11-04 | 2015-12-30 | Synthon BV | A process for making crystalline delta-form of ivabradine hydrochloride |
US9120755B2 (en) | 2011-11-14 | 2015-09-01 | Cadila Healthcare Limited | Polymorphic forms of ivabradine hydrochloride |
CN103183639B (en) * | 2011-12-30 | 2015-06-17 | 浙江京新药业股份有限公司 | Stable hydrochloric acid Ivabradine II crystal form and preparation method |
EP2948432B1 (en) | 2013-01-24 | 2018-09-19 | Synthon BV | Process for making ivabradine |
ITMI20130416A1 (en) * | 2013-03-19 | 2014-09-20 | Chemo Res S L | NEW POLIMORFO OF IVABRADINA CHLORIDRATE AND METHOD FOR ITS PREPARATION |
HUE047705T2 (en) * | 2013-03-19 | 2020-05-28 | Chemo Res S L | New polymorph of ivabradine hydrochloride and method for its preparation |
CZ2013767A3 (en) | 2013-10-02 | 2015-04-29 | Zentiva, K.S. | Solid form of ivabradine hydrochloride and (S)-mandelic acid as well as pharmaceutical composition thereof |
WO2015001133A1 (en) | 2013-12-12 | 2015-01-08 | Synthon B.V. | Pharmaceutical composition comprising amorphous ivabradine |
PT2774606T (en) | 2014-02-14 | 2019-05-06 | Synthon Bv | Pharmaceutical composition comprising ivabradine hydrochloride polymorph iv |
CZ2014478A3 (en) | 2014-07-10 | 2015-09-16 | Zentiva, K.S. | Ivabradine hydrochloride and (R)-mandelic acid solid form and pharmaceutical composition thereof |
US11273162B2 (en) * | 2016-04-01 | 2022-03-15 | Mississippi State University | Compositions and methods targeting HCN channels for breathing therapeutics |
EP3366282A1 (en) | 2017-02-28 | 2018-08-29 | Sanovel Ilac Sanayi ve Ticaret A.S. | Solid oral pharmaceutical compositions of ivabradine |
TR201703066A2 (en) | 2017-02-28 | 2018-09-21 | Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi | Solid oral pharmaceutical compositions of ivabradine |
WO2020092288A1 (en) | 2018-10-30 | 2020-05-07 | Amgen Inc. | Process of making ivabradine hydrochloride drug product |
CA3161960A1 (en) | 2019-12-16 | 2021-06-24 | Tenax Therapeutics, Inc. | Levosimendan for treating pulmonary hypertension with heart failure with preserved ejection fraction (ph-hfpef) |
IT202000025312A1 (en) | 2020-10-26 | 2022-04-26 | Cambrex Profarmaco Milano S R L | PROCESSES FOR THE PREPARATION OF IVABRADINE HCL POLYMORPHS |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4490369A (en) * | 1981-05-19 | 1984-12-25 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Benzazepine derivatives, their pharmaceutical compositions and method of use |
SU1160935A3 (en) * | 1981-05-19 | 1985-06-07 | Др.Карл Томэ Гмбх (Фирма) | Method of obtaining derivatives of benzazepone or their acid-additive salts with inorganic acids |
EP0534859A1 (en) * | 1991-09-27 | 1993-03-31 | Adir Et Compagnie | Benzocyclobutyl- or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2868777B1 (en) * | 2004-04-13 | 2006-05-26 | Servier Lab | NOVEL PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS SALTS OF ADDITION TO A PHARMACEUTICALLY ACCEPTABLE ACID |
FR2882554B1 (en) * | 2005-02-28 | 2007-05-04 | Servier Lab | IVABRADINE HYDROCHLORIDE BETA D-CRYSTALLINE FORM, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2882553B1 (en) * | 2005-02-28 | 2007-05-04 | Servier Lab | CRYSTALLINE BETA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2882556B1 (en) * | 2005-02-28 | 2007-05-04 | Servier Lab | CRYSTALLINE GAMMA D FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2882555B1 (en) * | 2005-02-28 | 2007-05-04 | Servier Lab | CRYSTALLINE GAMMA FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2891826B1 (en) * | 2005-10-11 | 2007-12-28 | Servier Lab | CRYSTALLINE FORM 6 OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
FR2891827B1 (en) * | 2005-10-11 | 2007-12-28 | Servier Lab | CRYSTALLINE DELTAD FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR PREPARING THE SAME, AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME |
-
2005
- 2005-02-28 FR FR0501989A patent/FR2882555B1/en not_active Expired - Fee Related
-
2006
- 2006-02-13 MA MA28795A patent/MA28134A1/en unknown
- 2006-02-14 JO JO200648A patent/JO2515B1/en active
- 2006-02-14 PE PE2006000171A patent/PE20061142A1/en not_active Application Discontinuation
- 2006-02-21 CR CR8249A patent/CR8249A/en unknown
- 2006-02-21 SG SG200601141A patent/SG125229A1/en unknown
- 2006-02-22 GT GT200600088A patent/GT200600088A/en unknown
- 2006-02-22 CU CU20060037A patent/CU23616B7/en active IP Right Grant
- 2006-02-22 US US11/358,955 patent/US7361650B2/en active Active
- 2006-02-22 AP AP2006003521A patent/AP1956A/en active
- 2006-02-22 TW TW095105986A patent/TWI314143B/en active
- 2006-02-24 CA CA002537400A patent/CA2537400C/en active Active
- 2006-02-24 UY UY29406A patent/UY29406A1/en not_active Application Discontinuation
- 2006-02-24 BR BRPI0600796A patent/BRPI0600796B8/en active IP Right Grant
- 2006-02-27 SA SA06270040A patent/SA06270040B1/en unknown
- 2006-02-27 KR KR1020060018718A patent/KR100835447B1/en active IP Right Grant
- 2006-02-27 NZ NZ545578A patent/NZ545578A/en unknown
- 2006-02-27 IL IL173959A patent/IL173959A0/en active IP Right Grant
- 2006-02-27 NO NO20060948A patent/NO338481B1/en unknown
- 2006-02-27 UA UAA200602126A patent/UA86595C2/en unknown
- 2006-02-27 EA EA200600320A patent/EA008465B1/en unknown
- 2006-02-27 GE GEAP20069265A patent/GEP20084467B/en unknown
- 2006-02-27 MY MYPI20060821A patent/MY158129A/en unknown
- 2006-02-28 ES ES06290328T patent/ES2308689T3/en active Active
- 2006-02-28 DK DK06290328T patent/DK1707562T3/en active
- 2006-02-28 RS RSP-2008/0365A patent/RS50598B/en unknown
- 2006-02-28 WO PCT/FR2006/000443 patent/WO2006092492A1/en not_active Application Discontinuation
- 2006-02-28 ZA ZA200601764A patent/ZA200601764B/en unknown
- 2006-02-28 PL PL06290328T patent/PL1707562T3/en unknown
- 2006-02-28 CN CNB2006100580784A patent/CN100402502C/en active Active
- 2006-02-28 CO CO06019930A patent/CO5770097A1/en not_active Application Discontinuation
- 2006-02-28 AT AT06290328T patent/ATE396974T1/en active
- 2006-02-28 ME MEP-2008-925A patent/ME02747B/en unknown
- 2006-02-28 SI SI200630042T patent/SI1707562T1/en unknown
- 2006-02-28 PT PT06290328T patent/PT1707562E/en unknown
- 2006-02-28 JP JP2006051649A patent/JP4628974B2/en active Active
- 2006-02-28 AR ARP060100730A patent/AR052926A1/en not_active Application Discontinuation
- 2006-02-28 DE DE602006001312T patent/DE602006001312D1/en active Active
- 2006-02-28 EP EP06290328A patent/EP1707562B1/en active Active
-
2007
- 2007-02-01 HK HK07101192A patent/HK1096659A1/en unknown
-
2008
- 2008-02-28 US US12/072,793 patent/US20080153803A1/en not_active Abandoned
- 2008-07-10 CY CY20081100726T patent/CY1109010T1/en unknown
- 2008-08-21 HR HR20080406T patent/HRP20080406T5/en unknown
-
2009
- 2009-08-27 US US12/583,885 patent/US7867996B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4490369A (en) * | 1981-05-19 | 1984-12-25 | Dr. Karl Thomae Gesellschaft Mit Beschrankter Haftung | Benzazepine derivatives, their pharmaceutical compositions and method of use |
SU1160935A3 (en) * | 1981-05-19 | 1985-06-07 | Др.Карл Томэ Гмбх (Фирма) | Method of obtaining derivatives of benzazepone or their acid-additive salts with inorganic acids |
EP0534859A1 (en) * | 1991-09-27 | 1993-03-31 | Adir Et Compagnie | Benzocyclobutyl- or indanyl-alkyl-amino-alkyl substituted 3-benzazepin-2-ones useful in the treatment of cardiovascular diseases |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2619121C2 (en) * | 2011-11-04 | 2017-05-12 | Уркуима, С.А. | Form iv of ivabradine hydrochloride |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA008465B1 (en) | γ-CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | |
EA008466B1 (en) | BETA d CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | |
EA008532B1 (en) | γd -CRYSTALLINE FORM OF IVABRADINE HYDROCHLORIDE, A PROCESS FOR ITS PREPARATION AND PHARMACEUTICAL COMPOSITION CONTAINING IT | |
EA008464B1 (en) | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
EA010296B1 (en) | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
EA010286B1 (en) | Delta d crystalline form of ivabradine hydrochloride, process of preparation thereof and pharmaceutical compositions containing the same | |
EA008474B1 (en) | Alpha crystalline form of strontium ranelate, a process for its preparation and pharmaceutical compositions containing it | |
MXPA06002274A (en) | Beta-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it | |
MXPA06002276A (en) | Gamma d-crystalline form of ivabradine hydrochloride, a process for its preparation and pharmaceutical compositions containing it |